Adenovirus-mediated TRAIL expression and downregulation of Bcl-2 expression suppresses non-small cell lung cancer growth in vitro and in vivo

International Journal of Molecular Medicine

Volumn 30, Issue 2, 2012, Pages 358-364

  Zhang, Haiping ^a   Sui, Aihua ^a   Wang, Zhenli ^b   Liu, Shihai ^a   Yao, Ruyong ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b First Sanatorium of Jinan Military District ^*  (China)

Author keywords

Adenovirus; B cell lymphoma 2; Non small cell lung cancer; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

ADENOVIRUS VECTOR; PROTEIN BCL 2; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER REGRESSION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSGENES;

EID: 84863544150     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.998     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Houwen L: State of the art: lung cancer in China. Ann Thorac Cardiovasc Surg 9: 147-148, 2003.
3. van DM, Karim-Kos HE, Siesling S, et al: Progress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 years. J Thorac Oncol 7: 291-298, 2012.
4. Bareschino MA, Schettino C, Rossi A, et al: Treatment of advanced non small cell lung cancer. J Thorac Dis 3: 122-133, 2011.
5. Nair BS, Bhanderi V and Jafri SH: Current and emerging pharmacotherapies for the treatment of relapsed small cell lung cancer. Clin Med Insights Oncol 5: 223-234, 2011.
6. Ashkenazi A, Pai RC, Fong S, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
7. Soria JC, Smit E, Khayat D, et al: Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 28: 1527-1533, 2010.
8. Pan G, O RK, Chinnaiyan AM, et al: The receptor for the cytotoxic ligand TRAIL. Science 276: 111-113, 1997.
9. Walczak H, Degli-Esposti MA, Johnson RS, et al: TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 16: 5386-5397, 1997.
10. Marsters SA, Sheridan JP, Pitti RM, et al: A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 7: 1003-1006, 1997.
11. Emery JG, McDonnell P, Burke MB, et al: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273: 14363-14367, 1998.
12. Zhang Y, Wang JH, Lu Q and Wang YJ: Bag3 promotes resistance to apoptosis through Bcl-2 family members in non-small cell lung cancer. Oncol Rep 1: 109-113, 2011.
13. Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 3: 614-620, 1997.
14. Griffith TS and Lynch DH: TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10: 559-563, 1998.
15. Carr LL, Finigan JH and Kern JA: Evaluation and treatment of patients with non-small cell lung cancer. Med Clin North Am 95: 1041-1054, 2011.
16. Daly BD, Cerfolio RJ and Krasna MJ: Role of surgery following induction therapy for stage III non-small cell lung cancer. Surg Oncol Clin N Am 20: 721-732, 2011.
17. Coleman MH and Bueno R: Role of adjuvant chemotherapy in NSCLC (stages I to III). Surg Oncol Clin N Am 20: 757-767, 2011.
18. Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2: 420-430, 2002.
19. McGrath EE: The tumor necrosis factor-related apoptosis-inducing ligand and lung cancer: still following the right TRAIL? J Thorac Oncol 6: 983-987, 2011.
20. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL and Iggo R: Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 34: 263-264, 2003.
21. Carette JE, Overmeer RM, Schagen FH, et al: Conditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cells. Cancer Res 64: 2663-2667, 2004.
22. Kaufmann SH and Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256: 42-49, 2000.
23. Gross A, McDonnell JM and Korsmeyer SJ: Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911, 1999.
24. Jansen B and Zangemeister-Wittke U: Antisense therapy for cancer - the time of truth. Lancet Oncol 3: 672-683, 2002.
25. Cory S and Adams JM: The Bcl-2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2: 647-656, 2002.